| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Ifosfamide (formerly NSC-109724, Isophosphamide; Ifomide; Iphosphamid; iphosphamide; Isoendoxan; IsoEndoxan; Naxamide; Cyfos; Ifex; Ifosfamidum) is an approved anticancer medication which acts as a nitrogen mustard and DNA alkylating agent/alkylator. It has been used to treat a number of cancers, including ovarian cancer, non-Hodgkin'sand Hodgkin's lymphomas, pediatric solid tumors, and mall cell lung cancer. Ifosfamide is a prodrug that needs to be converted to its active form, isofosforamide mustard, which alkylates DNA, in the liver by cytochrome P450 enzymes.
| Targets |
DNA Alkylator
|
|
|---|---|---|
| ln Vitro |
|
|
| ln Vivo |
|
|
| Cell Assay |
A medium containing 2 milliliters is used to seed 4 × 104 cells in a 3-cm dish. When it comes to final concentrations, 0 to 5 mM of ifosfamide are added the following day. After the medium has been removed and the cells have been cleaned with PBS and either counted or stained, six more days are allowed[2].
|
|
| Animal Protocol |
Rats: Female rats are separated into four groups of eight before mating: group 1 is an untreated negative control group; group 2 is an injection of 1 mL of 0.9% NaCl; group 3 is an injection of 25 mg/kg Ifosfamide; and group 4 is an injection of 50 mg/kg Ifosfamide. Following five days of daily injections of Ifosfamide, three females are kept in a cage with one untreated male for a maximum of one week. Every day, vaginal smears are checked to see if someone is pregnant. In the event that sperm are found, the first 24 hours after mating are considered the first day of pregnancy. The expectant mothers are kept apart and regularly checked for symptoms of toxicity and miscarriage. On the eighteenth day of gestation, all pregnant animals are sacrificed by being beheaded. Serum is decanted and kept at -70°C until it is needed for the hormone assay. Cardiac blood (2.5–3 mL/rat) is collected in nonheparinized test tubes, centrifuged at 3,000× g for 30 min. The uterus and both ovaries are removed after blood collection, cleaned in saline solution, and the corpora lutea of pregnancy are counted visually. Each uterine horn is then examined to determine the number of viable fetuses, implantation sites, and resorption sites. Crown rump (CR) length is measured, weight is recorded, and each fetus is extracted from its umbilical cord. The placental weights are noted and the fetuses are inspected for external malformation. In order to facilitate histological and immunohistochemical analysis, fetuses and placentas from the control and treated groups are fixed in 10% neutral broth formalin.
|
|
| References |
| Molecular Formula |
C7H15CL2N2O2P
|
|
|---|---|---|
| Molecular Weight |
261.09
|
|
| Exact Mass |
260.02
|
|
| Elemental Analysis |
C, 32.20; H, 5.79; Cl, 27.16; N, 10.73; O, 12.26; P, 11.86
|
|
| CAS # |
3778-73-2
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1CN(P(=O)(OC1)NCCCl)CCCl
|
|
| InChi Key |
HOMGKSMUEGBAAB-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)
|
|
| Chemical Name |
N,3-bis(2-chloroethyl)-2-oxo-1,3,2lambda5-oxazaphosphinan-2-amine
|
|
| Synonyms |
NSC-109724; Isophosphamide; Ifomide; NSC 109724; NSC109724; Iphosphamid; iphosphamide; Isoendoxan; IsoEndoxan; isophosphamide; Naxamide; Trade names: Cyfos; Ifex; Ifosfamidum
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 25 mg/mL (95.75 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8301 mL | 19.1505 mL | 38.3010 mL | |
| 5 mM | 0.7660 mL | 3.8301 mL | 7.6602 mL | |
| 10 mM | 0.3830 mL | 1.9150 mL | 3.8301 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01873326 | Active Recruiting |
Drug: Paclitaxel Drug: Ifosfamide |
Germ Cell Tumors | Memorial Sloan Kettering Cancer Center |
June 2013 | Phase 2 |
| NCT02227199 | Active Recruiting |
Drug: Brentuximab Vedotin Drug: Carboplatin |
Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma |
University of Washington | October 10, 2014 | Phase 1 Phase 2 |
| NCT01959698 | Active Recruiting |
Drug: Carboplatin Drug: Carfilzomib |
CD20 Positive | Roswell Park Cancer Institute | April 17, 2014 | Phase 1 |
| NCT03016871 | Active Recruiting |
Drug: Carboplatin Drug: Etoposide |
Recurrent Hodgkin Lymphoma Refractory Hodgkin Lymphoma |
City of Hope Medical Center | March 2009 | Phase 2 |
| NCT04665765 | Active Recruiting |
Drug: Carboplatin Drug: Etoposide |
Refractory Diffuse Large B- Cell Lymphoma |
City of Hope Medical Center | January 18, 2021 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA